AllergyTalk
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
Episodes
Thursday Feb 18, 2021
Episode 16: Comorbid Laryngeal Dysfunction in Asthma
Thursday Feb 18, 2021
Thursday Feb 18, 2021
Show notes for Episode 16:
For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!
Article links:
Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis.
Trends and Disparities in Asthma Biologic Use in the United States.
Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara has nothing to disclose
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Thursday Feb 18, 2021
Episode 15: Prenatal Exposure to Air Pollution
Thursday Feb 18, 2021
Thursday Feb 18, 2021
For today’s episode we will be reviewing three more articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!
Article links:
Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age
Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma
Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara has nothing to disclose
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Thursday Jan 07, 2021
Episode 14: Food allergy and anaphylaxis, plus success of peanut OIT
Thursday Jan 07, 2021
Thursday Jan 07, 2021
For today’s episode we will be reviewing three articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!
Article links:
Earlier Ingestion of Peanut After Changes to Infant Feeding Guidelines: The EarlyNuts Study
Effect of Sleep Deprivation and Exercise on Reaction Threshold in Adults With Peanut Allergy: A Randomized Controlled Study
Treatment With a Platelet-Activating Factor Receptor Antagonist Improves Hemodynamics and Reduces Epinephrine Requirements, in a Lethal Rodent Model of Anaphylactic Shock
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara has nothing to disclose
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Wednesday Sep 09, 2020
Episode 13, Part 2 – Delayed Drug Hypersensitivity with Dr. David Khan, MD
Wednesday Sep 09, 2020
Wednesday Sep 09, 2020
Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!
The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.
Wednesday Sep 09, 2020
Episode 13, Part 1 – Delayed Drug Hypersensitivity with Dr. David Khan, MD
Wednesday Sep 09, 2020
Wednesday Sep 09, 2020
Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!
The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.
Tuesday May 26, 2020
Episode 12 - Changing Biologics, Mucus Viscosity, Pemphigus and Food Allergy
Tuesday May 26, 2020
Tuesday May 26, 2020
For today’s episode we will be reviewing three more articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk
Article Links:
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Altered Viscosity of Nasal Secretions in Postnasal Drip.
Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Tuesday May 26, 2020
Episode 11: Step Up Therapy In Asthma, A Therapy For Habit Cough
Tuesday May 26, 2020
Tuesday May 26, 2020
For today’s episode we will be reviewing three articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk
Article links:
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.
Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.
Unexpected and unintended cure of habit cough by proxy.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Thursday Apr 30, 2020
Cough Miniseries – Episode 3: Treatment Options Cough
Thursday Apr 30, 2020
Thursday Apr 30, 2020
In the third of three podcasts focusing on Cough, host Dr. Purvi Parikh joins with Dr. Kevin Murphy and Dr. Mandel Sher to look at the what does and doesn’t work in treating cough. They review the current therapies and what new therapies options are coming in the future.
This podcast is supported by an educational grant from Merck & Co., Inc.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron
Purvi Parikh, MD
Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca
Mandel Sher, MD
Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe
Thursday Apr 30, 2020
Cough Miniseries – Episode 2: Diagnosing the Patient's Cough
Thursday Apr 30, 2020
Thursday Apr 30, 2020
In this, the second of three podcasts focusing on Cough, host Dr. Purvi Parikh discusses diagnosing cough with Dr. Mandel Sher and Dr. Kevin Murphy. They address diagnosing chronic cough in children and adults. Protracted bacterial bronchitis, the role of GERD in cough, and habit cough are also discussed.
This podcast is supported by an educational grant from Merck & Co., Inc.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron
Purvi Parikh, MD
Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca
Mandel Sher, MD
Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe
Thursday Apr 30, 2020
Cough Miniseries – Episode 1: Understanding the Cough Reflex
Thursday Apr 30, 2020
Thursday Apr 30, 2020
In this, the first of three podcasts focusing on Cough, host Dr. Purvi Parikh speaks with Dr. Mandel Sher and Dr. Kevin Murphy about the “true” cough reflex, the cough response, and cough hypersensitivity.
This podcast is supported by an educational grant from Merck & Co., Inc.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron
Purvi Parikh, MD
Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca
Mandel Sher, MD
Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe







